symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
HLVX,12.03,0,59250,582455307,0,11.21-23.1,-0.13,"HilleVax, Inc.",USD,0001888012,US43157M1027,43157M102,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.hillevax.com,"HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.","Dr. Robert M. Hershberg M.D., Ph.D.",Healthcare,US,62,617 213 5054,75 State Street,Boston,MA,02109,,0,https://financialmodelingprep.com/image-stock/HLVX.png,2022-04-29,False,False,True,False,False
